eligibility_summary
Eligible: WHO-defined MDS (new, relapsed, or refractory) with IPSS-R >3.5, age 14–80, KPS ≥60% or ECOG ≤2, survival ≥3 mo, labs: ALT/AST ≤3×ULN, bilirubin ≤3×ULN, creatinine ≤2×ULN or CrCl ≥40 mL/min, LVEF >50%, 0–3/10 HLA-matched, same blood type donor, consent. Exclude: other malignancy, chemo aplasia, surgery <4 wks, serious non-MDS illness, drug allergy, serious heart disease, HIV/HBV/HCV+, stroke/ICH <6 mo, need warfarin/VKA, psych illness, recent/ongoing trial, other unsuitable.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2, single-arm trial in higher-risk MDS testing: 1) Unrelated umbilical cord blood microtransplantation (biologic cell therapy): HLA-mismatched UCB infused during chemotherapy without immunosuppression to create transient donor microchimerism, augment hematopoiesis, and elicit graft‑versus‑MDS immune effects via donor NK/T cells (no durable engraftment intended). 2) Venetoclax (small-molecule BCL‑2 inhibitor): blocks anti‑apoptotic BCL‑2 to trigger mitochondrial apoptosis in MDS blasts. 3) Decitabine or Azacitidine (nucleoside analog hypomethylating agents, DNMT inhibitors): induce DNA hypomethylation, re-express silenced genes, promote differentiation/apoptosis and immunogenicity. Targets: MDS stem/progenitor cells, intrinsic apoptosis (BCL‑2 pathway), DNA methylation/DNMT1, donor NK/T cell–mediated graft‑versus‑MDS.